

Clinical trials of eprosartan+ACE inhibitor

TrialResults-center www.trialresultscenter.org

1 heart failure

Trial	Treatments	Patients	Trials design and methods
eprosartan+ACE inhibitor vs ACE inhibitor only			
ADEPT, 2001 n=18/18 follow-up: 8 wk	Eprosartan, 400 to 800 mg twice daily versus Placebo	patients with stable New York Heart Association class II-IV CHF receiving ACE inhibitor therapy	Parallel groups double blind

More details and results :

- angiotensin-receptor blockers for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q65>
- angiotensin-receptor blockers for heart failure in patients already receiving ACE inhibitor at <http://www.trialresultscenter.org/go-Q68>

References

ADEPT, 2001:

Murdoch DR, McDonagh TA, Farmer R, Morton JJ, McMurray JJ, Dargie HJ ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Am Heart J 2001 May;141:800-7 [[11320369](#)]